Exogenous pulmonary surfactant replacement therapy represents one of the most transformative triumphs in modern neonatology, converting neonatal respiratory distress syndrome (RDS) from a fatal hyaline membrane disease into a manageable developmental condition. However, the historical mandate of endotracheal intubation and mechanical ventilation for surfactant delivery introduces significant risks of positive-pressure volutrauma, barotrauma, biotrauma, and tracheal mucosal injury. Over the past two decades, surfactant administration has undergone an evolutionary paradigm shift toward non-invasive and minimally invasive techniques—most notably Less Invasive Surfactant Administration (LISA) and Minimally Invasive Surfactant Therapy (MIST)—which preserve spontaneous diaphragmatic respiration on continuous positive airway pressure (CPAP), mitigate lung injury cascades, and substantially reduce the incidence of bronchopulmonary dysplasia (BPD) and death.

Evolution of Surfactant Delivery Modalities

The progression of exogenous surfactant delivery reflects an ongoing effort to balance rapid, homogeneous alveolar recruitment with the minimization of mechanical ventilator-induced lung injury (VILI).

graph TD
    A["Era 1: Mandatory Mechanical Ventilation<br/>(Late 1980s - 1990s)"] -->|"Attempt to avoid prolonged MV"| B["Era 2: INSURE Method<br/>(INtubate-SURfactant-Extubate, ~1994)"]
    B -->|"Overcome Extubation Failure & Sedative Depression"| C["Era 3: LISA / MIST Thin Catheter Delivery<br/>(Cologne & Hobart Techniques, 2000s-Present)"]
    C -->|"Eliminate Laryngoscopy Entirely"| D["Era 4: Non-Invasive Delivery<br/>(LMA, Aerosolization, Pharyngeal Instillation)"]

    style A fill:#fee2e2,stroke:#ef4444,stroke-width:2px;
    style B fill:#fef3c7,stroke:#f59e0b,stroke-width:2px;
    style C fill:#dcfce7,stroke:#22c55e,stroke-width:2px;
    style D fill:#e0e7ff,stroke:#6366f1,stroke-width:2px;

1. Classic Endotracheal Intubation and Invasive Mechanical Ventilation

In early randomized trials (e.g., OSIRIS, Collaborative European trials), exogenous surfactant (poractant alfa, beractant, calfactant, or lucinactant) was instilled directly through an endotracheal tube (ETT) followed by ongoing invasive positive-pressure ventilation (IPPV).

Pathophysiological Trade-Off: While delivering rapid alveolar recruitment and improving the ventilation-perfusion ($\dot{V}_A/\dot{Q}$) matching, the sheer shear stress of high peak inspiratory pressures ($PIP$), large tidal volumes ($V_T$), and non-uniform opening and closing of unrecruited alveoli (atelectrauma) initiated inflammatory cytokine cascades (interleukin-6, interleukin-8, tumor necrosis factor-$\alpha$), accelerating the pathogenesis of classical and "new" BPD.

2. The INSURE Technique (INtubate–SURfactant–Extubate)

Introduced by Victorin and colleagues in the 1990s, the INSURE strategy aimed to provide early surfactant replacement while avoiding long-term mechanical ventilation:

Direct laryngoscopy and oral endotracheal intubation.
Surfactant instillation via an ETT catheter or side-port adaptor accompanied by brief positive-pressure bagging or mechanical ventilation ($1-5\text{ minutes}$).
Immediate or rapid extubation back to nasal CPAP once clinical stabilization occurs.

The Achilles' Heel of INSURE: Extubation Failure

Despite its conceptual elegance, INSURE carries an extubation failure rate of $20-30\%$ within the first $24-72\text{ hours}$ in extremely low birth weight (ELBW, $<1000\text{ g}$) and very low birth weight (VLBW, $<1500\text{ g}$) infants. The primary drivers of INSURE failure include:

Pharmacological Respiratory Depression: Procedural premedication (opioids, benzodiazepines, or anesthetics) blunts central chemoreceptor sensitivity and abolishes spontaneous diaphragmatic effort.
Laryngeal & Subglottic Edema: Even brief ETT instrumentation breaches the fragile non-keratinized ciliated epithelium, inducing reactive airway edema, loss of vocal cord abductor tone, and post-extubation upper airway collapse.
Positive Pressure Volutrauma: The brief positive-pressure inflations delivered during surfactant dispersion can cause overdistension of compliant lung units before surfactant is homogeneously distributed.

3. LISA and MIST (Thin-Catheter Surfactant Administration)

The realization that spontaneous diaphragmatic breathing generates continuous negative intrapleural swings ($P_{pl}$) that optimize fluid-film capillarity and surfactant spreading led to the development of thin-catheter instillation techniques while maintaining uninterrupted nasal Bubble CPAP or non-invasive positive pressure support ($6-8\text{ cmH}_2\text{O}$):

Cologne Technique (LISA): Developed by Angela Kribs and colleagues (Cologne, Germany). Uses a soft, flexible vascular catheter (e.g., 4–5 Fr feeding tube or specialized vascular catheter such as Surfcath/Lisacath) positioned $1.0-1.5\text{ cm}$ below the vocal cords using direct laryngoscopy and Magill forceps while the infant breathes spontaneously on CPAP.
Hobart Technique (MIST): Developed by Peter Dargaville and colleagues (Hobart, Australia). Utilizes a semi-rigid vascular catheter (e.g., 16–18G Angiocath or 31–33 cm semi-rigid Melbourne catheter) that can be directly guided through the glottic aperture without requiring Magill forceps, reducing mucosal trauma and procedural complexity.

4. Alternative Non-Invasive Delivery Modalities

Laryngeal Mask Airway (LMA) Surfactant Delivery: Suited for larger preterm infants ($\ge 32-34\text{ weeks}$ gestation or birth weight $\ge 1.2-1.5\text{ kg}$). A size 1 LMA is inserted blindly into the hypopharynx, creating a supraglottic seal through which surfactant is instilled without vocal cord instrumentation or premedication, followed by immediate removal back to CPAP.
Aerosolized / Nebulized Surfactant Delivery: Utilizing vibrating mesh nebulizers placed in-line with nasal CPAP or high-flow nasal cannula (HFNC). While non-invasive and non-stressful, alveolar deposition efficiency remains historically low ($5-15\%$) due to upper airway particle impaction, though second-generation synthetic surfactants and customized breath-synchronized aerosol generators continue to advance.
Pharyngeal Surfactant Instillation: Instillation of surfactant into the posterior nasopharynx prior to the first extrauterine breath in the delivery room, relying on natural inspiratory negative pressure to aspirate surfactant into the bronchial tree.

Comparative Matrix: Surfactant Administration Techniques

Feature / Modality	Classic ETT Ventilation	INSURE Technique	LISA / MIST (Thin Catheter)	Laryngeal Mask Airway (LMA)	Aerosolized Nebulization
Airway Device	Standard ETT (2.5–3.5 mm)	Standard ETT (2.5–3.5 mm)	Thin vascular catheter (16–18G, 4–5 Fr)	Size 1 Supraglottic Mask	Vibrating mesh nebulizer on CPAP circuit
Breathing Mode	Fully passive or assist-control IPPV	Positive-pressure bagging $\rightarrow$ Extubation	Active, continuous spontaneous breathing on CPAP	Spontaneous breathing or brief PPV	Spontaneous breathing on CPAP
Premedication Needed	Full analgesia + sedation $\pm$ NMB	Sedation + short-acting analgesia	Non-pharmacological (sucrose/swaddling) or light analgosedation	Minimal to none	None
Glottic Trauma Risk	High (cuffed/uncuffed ETT friction)	Moderate-High (intubation + rapid extubation)	Minimal (ultra-thin catheter caliber)	Absent (supraglottic placement)	Zero (no direct contact)
Distribution Mechanism	Positive-pressure meniscus push	Positive-pressure bulk flow	Spontaneous negative inspiratory gradient + Marangoni effect	Direct tracheal spillover + spontaneous breaths	Micro-aerosol droplet inhalation ($<3\,\mu\text{m}$)
BPD / Death Reduction	Baseline comparator	Modest reduction vs continued MV	Significant reduction ($\text{RR } 0.65-0.75$)	Comparable to INSURE in $\ge 32\text{ wk}$	Under active clinical investigation
Typical Failure Rate	N/A (invasive by definition)	$20-30\%$ extubation failure within $72\text{ h}$	$15-25\%$ progression to mechanical ventilation	$20-30\%$ conversion to ETT	Highly variable ($30-50\%$)

Physiological Mechanics: Spontaneous Negative Pressure vs Positive Pressure

The biophysical distribution of exogenous surfactant is fundamentally governed by fluid mechanics, capillary spreading, and the transpulmonary pressure gradient ($\Delta P_L = P_{ao} - P_{pl}$).

The Marangoni Effect and Capillary Liquid-Film Dynamics

When surfactant is instilled into the liquid layer lining the respiratory tree, it generates a surface tension gradient ($\Delta \gamma = \gamma_{\text{pure fluid}} - \gamma_{\text{surfactant}}$). This surface tension discontinuity exerts a spreading velocity ($u_s$) along the air-liquid interface known as Marangoni convection:

$$u_s \approx \frac{h}{\mu} \frac{d\gamma}{dx}$$

Where:

$h$ = liquid film thickness lining the airway epithelium ($\mu\text{m}$)
$\mu$ = dynamic viscosity of alveolar lining fluid ($\text{Pa}\cdot\text{s}$)
$\frac{d\gamma}{dx}$ = spatial gradient of surface tension ($\text{mN}/(\text{m}\cdot\text{cm})$)

In spontaneously breathing infants on CPAP (LISA/MIST), cyclic diaphragmatic contractions generate negative pleural pressure swings ($P_{pl} < 0$), actively pulling the fluid meniscus into dependent and peripheral bronchioles via negative suction. In contrast, positive-pressure mechanical ventilation (INSURE/ETT) pushes surfactant down paths of least resistance into already open, hypercompliant lung units, worsening regional overdistension while under-treating collapsed, high-elastance lung zones.

graph TD
    subgraph LISA_Spontaneous_Breathing["LISA / MIST: Spontaneous Breathing on CPAP"]
        L1["Spontaneous Diaphragmatic Contraction"] --> L2["Negative Pleural Pressure Swings (Ppl < 0)"]
        L2 --> L3["Active Meniscus Inflow & Capillary Aspiration"]
        L3 --> L4["Homogeneous Distribution to Dependent & Collapsed Alveoli"]
        L4 --> L5["Preserved Endogenous FRC + Minimal Barotrauma"]
    end

    subgraph INSURE_Positive_Pressure["INSURE: Positive-Pressure Bagging / ETT"]
        I1["Positive Airway Pressure Inflation (Paw > 0)"] --> I2["Surfactant Directed Along Path of Least Resistance"]
        I2 --> I3["Preferential Over-Ventilation of Non-Dependent Units"]
        I3 --> I4["Regional Volutrauma / Atelectrauma in Collapsed Units"]
        I4 --> I5["Sedation-Induced Apnea & Extubation Failure"]
    end

    style LISA_Spontaneous_Breathing fill:#f0fdf4,stroke:#16a34a,stroke-width:2px;
    style INSURE_Positive_Pressure fill:#fef2f2,stroke:#dc2626,stroke-width:2px;

Landmark Trials & Evidence-Based Synthesis

The efficacy of LISA and MIST has been rigorously established in randomized controlled trials and large-scale international meta-analyses:

timeline
    title Landmark Milestones in Thin-Catheter Surfactant Therapy
    2007 : Cologne Pioneer Cohort (Kribs et al.) : First demonstration of thin catheter delivery in ELBW infants on CPAP.
    2011 : AMV Trial (Göpel et al. Lancet) : LISA reduced mechanical ventilation need from 73% to 46% (p < 0.0001).
    2015 : NINSAPP Trial (Kribs et al. JAMA Pediatr) : Survival without BPD increased in 23-26 wk ELBW infants (67% vs 59%).
    2021 : OPTIMIST-A Trial (Dargaville et al. JAMA) : MIST reduced mechanical ventilation within 72h (33.5% vs 44.5%, p = 0.007).
    2023-2026 : Umbrella Reviews & Cochrane : LISA firmly endorsed as gold-standard first-line therapy across international guidelines.

Landmark Clinical Trials Summary

Landmark Study	Study Population	Intervention vs Control	Primary Endpoint & Key Findings	Clinical Significance
AMV Trial (Göpel et al., Lancet 2011)	220 infants ($26^{+0}-28^{+6}\text{ wk}$)	LISA via 5 Fr catheter on CPAP vs Standard ETT ventilation	Need for MV within 72h: $28\%$ (LISA) vs $46\%$ (Control), $p=0.008$. Less oxygen at 28 days ($30\%$ vs $45\%$).	First large multicenter trial proving LISA prevents mechanical ventilation in VLBW infants.
NINSAPP Trial (Kribs et al., JAMA Pediatr 2015)	211 extremely preterm infants ($23^{+0}-26^{+6}\text{ wk}$)	LISA (Cologne method) vs Standard intubation + INSURE	Survival without BPD at 36 wk: $67.3\%$ (LISA) vs $58.8\%$ (Control), $p=0.02$. Major reduction in severe IVH ($10.4\%$ vs $22.7\%$).	Proved feasibility and neuroprotective/pulmonary superiority of LISA in ELBW ($<27\text{ weeks}$) neonates.
OPTIMIST-A Trial (Dargaville et al., JAMA 2021)	485 preterm infants ($25^{+0}-28^{+6}\text{ wk}$) on CPAP	Hobart MIST (16G angiocatheter) vs Sham / CPAP alone	Intubation within 72h: $33.5\%$ (MIST) vs $44.5\%$ (Control), $p=0.007$. Physiological CPAP failure significantly averted.	Validated semi-rigid catheter MIST without Magill forceps across 33 global tertiary NICUs.
Cochrane & Umbrella Meta-Analyses (2023–2026)	$>5,000$ preterm infants across $>25\text{ RCTs}$	LISA / MIST vs INSURE / Standard Care	Composite Death or BPD at 36 wk: $\text{RR } 0.72$ ($95\%\text{ CI: } 0.63-0.82$). MV within 72h: $\text{RR } 0.65$ ($95\%\text{ CI: } 0.58-0.74$). Significant reduction in Grade 3–4 IVH and in-hospital mortality.	Consolidated LISA as Level 1A evidence in European Consensus RDS Guidelines.

💡 OPTIMIST-A Trial Clinical Pearl: The $FiO_2$ Threshold Trigger

In the OPTIMIST-A trial, early MIST administered when $FiO_2 \ge 0.30$ within the first $6\text{ hours}$ of life in infants $25-28\text{ weeks}$ significantly arrested progressive atelectasis, halving the need for later rescue intubation. Waiting for severe respiratory failure ($FiO_2 > 0.50$) negates the protective benefits of thin-catheter delivery.

Step-by-Step Practical LISA / MIST Procedure Protocol

Implementing LISA/MIST demands meticulous multidisciplinary teamwork between the procedural neonatologist, bedside nurse, and respiratory therapist.

Surfactant Administration Techniques (LISA, MIST, INSURE) Figure 1: Depth calibration and external flag placement during Less-Invasive Surfactant Administration (LISA). To prevent distal bronchial migration and avoid selective right mainstem instillation or airway perforation, an external sterile flag label is affixed to the 16–18G vascular angiocatheter at the calculated lip-to-tip depth [$\text{Depth (cm)} = \text{Weight (kg)} + 5.5-6.0\text{ cm}$, or $1.0-1.5\text{ cm}$ past the vocal cords]. The flag is kept strictly external to the infant's mouth while continuous positive airway pressure (CPAP $6-8\text{ cmH}_2\text{O}$) and spontaneous respiration are maintained.

flowchart TD
    A["Phase 1: Patient Selection & Sizing<br/>GA 24-34 wk, CPAP 6-8 cmH2O, FiO2 >= 0.30"] --> B["Phase 2: Premedication & Preparation<br/>Swaddling + Oral Sucrose (24%) +/- Low-Dose Analgosedation"]
    B --> C["Phase 3: Video Laryngoscopy & Cord Visualization<br/>Insert non-touch blade, inspect glottis"]
    C --> D["Phase 4: Catheter Insertion & Depth Check<br/>Pass 1.0-1.5 cm beyond vocal cords (Flag at Lip)"]
    D --> E["Phase 5: Slow Fractional Instillation<br/>Instill surfactant over 1-3 min synchronized with inspiration"]
    E --> F{"Procedural Assessment"}
    F -->|"SpO2 > 88%, HR > 100 bpm, No Reflux"| G["Complete Instillation & Withdraw Catheter"]
    F -->|"Bradycardia / Desaturation / Pharyngeal Reflux"| H["Pause Instillation -> Increase FiO2/CPAP -> Suction Pharynx"]
    H --> F
    G --> I["Phase 6: Post-Procedural CPAP Optimization<br/>Wean FiO2 rapidly as compliance increases"]

    style A fill:#f8fafc,stroke:#64748b,stroke-width:2px;
    style B fill:#eff6ff,stroke:#3b82f6,stroke-width:2px;
    style C fill:#f0fdf4,stroke:#22c55e,stroke-width:2px;
    style D fill:#fefce8,stroke:#eab308,stroke-width:2px;
    style E fill:#ecfdf5,stroke:#10b981,stroke-width:2px;
    style G fill:#dcfce7,stroke:#16a34a,stroke-width:2px;
    style H fill:#fef2f2,stroke:#ef4444,stroke-width:2px;
    style I fill:#f5f3ff,stroke:#8b5cf6,stroke-width:2px;

Phase 1: Patient Selection & Preparation

Inclusion Criteria: Spontaneously breathing preterm infants ($24^{+0}$ to $34^{+6}\text{ weeks}$) on nasal Bubble CPAP or non-invasive ventilation (NIV) with positive end-expiratory pressure $6-8\text{ cmH}_2\text{O}$ and $FiO_2 \ge 0.30$ ($<28\text{ weeks}$) or $FiO_2 \ge 0.35$ ($\ge 28\text{ weeks}$) with clinical and/or radiological signs of RDS.
Pre-Warming & Positioning: Pre-warm surfactant (poractant alfa $200\text{ mg/kg} = 2.5\text{ mL/kg}$ or beractant $100\text{ mg/kg} = 4.0\text{ mL/kg}$) to room/body temperature ($37^\circ\text{C}$). Position the neonate in the "sniffing position" with a small shoulder roll.

Phase 2: The Premedication Strategy

The ideal premedication regime provides analgesia and blunts stress responses without extinguishing spontaneous respiratory drive:

First-Line Non-Pharmacological Bundle (Recommended standard):
- Facilitated tucking / nested swaddling.
- Oral $24\%$ sucrose ($0.1-0.2\text{ mL}$ onto anterior tongue $2\text{ minutes}$ prior to laryngoscopy) combined with non-nutritive sucking.
Light Pharmacological Sedation (Unit-specific protocol):
- Ketamine: $0.5-1.0\text{ mg/kg}$ IV over $2\text{ minutes}$ (preserves pharyngeal muscle tone and spontaneous ventilation while providing profound analgesia and bronchodilation).
- Low-Dose Fentanyl: $0.5-1.0\,\mu\text{g/kg}$ IV slow push (monitor closely for chest wall rigidity and central apnea).
- Remifentanil: $0.025-0.05\,\mu\text{g/kg/min}$ ultra-short-acting infusion titrated strictly to maintain spontaneous breaths.
- Atropine: $10-20\,\mu\text{g/kg}$ IV (optional, reduces vagally mediated bradycardia and excessive secretions).

Fatal Pitfall: Neuromuscular Blockade is Strictly Contraindicated

Neuromuscular blocking agents (e.g., vecuronium, rocuronium, succinylcholine) and high-dose induction hypnotics (propofol, thiopental) completely paralyze or arrest spontaneous respiratory drive. Administration during LISA converts a minimally invasive procedure into an emergent un-intubated airway crisis!

Phase 3 & 4: Catheter Depth Calculation & Placement

Catheter depth must be strictly calibrated before entering the oral cavity:

$$\text{Catheter Depth at Lip (cm)} = \text{Body Weight (kg)} + 5.5 \text{ to } 6.0\text{ cm}$$$$\text{Alternatively: Catheter Distance Past Vocal Cords} = 1.0 \text{ to } 1.5\text{ cm (Absolute)}$$

Catheter Depth Guide by Birth Weight:
• < 750 g:   5.5 - 6.0 cm at lip (1.0 cm below cords)
• 750-1000 g: 6.0 - 6.5 cm at lip (1.2 cm below cords)
• 1000-1500 g: 6.5 - 7.0 cm at lip (1.5 cm below cords)
• > 1500 g:   7.0 - 7.5 cm at lip (1.5 - 2.0 cm below cords)

Laryngoscopy: Insert the Miller blade (Size 00 for $<1000\text{ g}$, Size 0 for $1000-2000\text{ g}$) or Video Laryngoscope into the vallecula to expose the vocal cords.
Catheter Insertion:
- LISA (Cologne): Advance a flexible 4–5 Fr catheter using Magill forceps through the glottis under direct vision until the pre-measured depth marker aligns with the vocal cords.
- MIST (Hobart): Advance a semi-rigid 16–18G Angiocath directly through the cords without forceps.
Laryngoscope Removal: Carefully withdraw the laryngoscope blade while stabilizing the catheter firmly against the upper gingiva or infant's cheek to avoid accidental displacement.

Phase 5: Instillation Technique & CPAP Maintenance

Maintain continuous nasal CPAP ($6-8\text{ cmH}_2\text{O}$) throughout. An assistant maintains an airtight mouth closure ("chin lift" / lip seal) to preserve end-expiratory circuit pressure.
Instill surfactant in small fractional aliquots ($0.2-0.5\text{ mL}$ per bolus) over $1-3\text{ minutes}$, synchronizing boluses with the infant's spontaneous inspiratory efforts.
Following complete instillation, flush the dead space of the catheter with $0.2-0.5\text{ mL}$ of air and immediately remove the catheter.

Intra-Procedural Complications & Bedside Rescue Tree

graph TD
    A["Intra-Procedural Adverse Event During LISA"] --> B{"Identify Primary Phenomenon"}
    
    B -->|"Event 1: Acute Bradycardia (HR < 100 bpm)"| C["Vagal Reflex / Hypoxia Trigger"]
    C --> C1["1. Pause surfactant instillation immediately<br/>2. Increase FiO2 by 10-20%<br/>3. Verify CPAP seal & baseline rate<br/>4. If HR < 60 bpm: Administer positive-pressure ventilation"]

    B -->|"Event 2: Severe Desaturation (SpO2 < 80%)"| D["Transient Airway Fluid Loading"]
    D --> D1["1. Halt bolus delivery<br/>2. Increase CPAP from 6-7 to 8-9 cmH2O<br/>3. Elevate FiO2 to maintain SpO2 90-95%<br/>4. Resume slow instillation once SpO2 recovers"]

    B -->|"Event 3: Surfactant Reflux into Pharynx / Mouth"| E["Instillation Rate Exceeds Clearance"]
    E --> E1["1. Pause instillation immediately<br/>2. Clear oral cavity with gentle bulb suction<br/>3. Check catheter tip depth (avoid esophageal placement)<br/>4. Increase CPAP +1 cmH2O to aid distal clearance<br/>5. Slow instillation rate to 30-45 s per mL"]

    B -->|"Event 4: Sustained Apnea / Procedural Failure"| F["Loss of Spontaneous Respiratory Drive"]
    F --> F1["1. Remove thin catheter<br/>2. Initiate Bag-Mask / T-Piece Neopuff Resuscitation<br/>3. If no recovery within 30-60 s: Perform Emergent Endotracheal Intubation"]

    style A fill:#f8fafc,stroke:#475569,stroke-width:2px;
    style C1 fill:#fee2e2,stroke:#ef4444,stroke-width:2px;
    style D1 fill:#fef3c7,stroke:#f59e0b,stroke-width:2px;
    style E1 fill:#ffedd5,stroke:#f97316,stroke-width:2px;
    style F1 fill:#fecdd3,stroke:#e11d48,stroke-width:2px;

Acute Reflux & Desaturation Management Bundle

Reflux of surfactant into the posterior pharynx occurs in $10-20\%$ of LISA procedures when instillation velocity exceeds capillary clearance kinetics. Follow the 4-Step Reflux Rescue:

Immediate Injection Pause: Stop pushing plunger instantly; do not force liquid down.
Clear Supraglottic Pool: Gently suction the oral cavity to prevent laryngospasm or pulmonary aspiration of gastric juices.
CPAP Boost: Increase PEEP/CPAP by $+1-2\text{ cmH}_2\text{O}$ to expand alveolar volume and generate greater driving gradient for liquid clearance.
Micro-Bolus Resumption: Resume instillation at half the previous rate ($0.1\text{ mL}$ micro-boluses synchronized with inspiratory excursions).

Post-Procedural Care & Criteria for LISA Failure

Following successful surfactant instillation, lung compliance ($C_{rs}$) and functional residual capacity ($FRC$) increase rapidly within $15-30\text{ minutes}$.

Post-Procedural Monitoring Protocol

Rapid $FiO_2$ Weaning: Continuously monitor $SpO_2$ (target $90-95\%$). As alveolar recruitment occurs, transpulmonary shunt drops precipitously; wean $FiO_2$ in $5-10\%$ increments every $2-5\text{ minutes}$ to avoid hyperoxic retinal and cerebral injury.
CPAP Titration: Maintain baseline CPAP ($6-8\text{ cmH}_2\text{O}$) for at least $2-4\text{ hours}$ post-procedure before attempting any wean to avoid secondary alveolar de-recruitment.
Surfactant Re-Dosing (Second Dose):
- Indicated if infant exhibits persistent or worsening RDS ($FiO_2 > 0.30-0.40$ on CPAP $\ge 7\text{ cmH}_2\text{O}$, respiratory acidosis with $pH < 7.20$ and $PaCO_2 > 60\text{ mmHg}$) $6-12\text{ hours}$ after the first dose.
- Second dose can be delivered via repeat LISA if spontaneous respiratory effort remains robust.

Definition and Thresholds for LISA Failure

LISA failure is defined as the requirement for endotracheal intubation and mechanical ventilation within $72\text{ hours}$ of thin-catheter delivery:

Criteria for Conversion to Invasive Mechanical Ventilation (LISA Failure):
1. Severe Hypoxemia: FiO2 >= 0.50 on optimized CPAP / NIV >= 8 cmH2O to maintain SpO2 >= 88%
2. Uncompensated Respiratory Acidosis: pH < 7.20 with PaCO2 > 65 mmHg on arterial / capillary blood gas
3. Refractory Apnea: Recurrent severe apneas (> 2-3 episodes/hour requiring vigorous stimulation or positive-pressure ventilation)
4. Severe Respiratory Exhaustion: Marked sternal/subcostal retractions, grunting, and clinical fatigue

Comprehensive Summary & Clinical Action Plan

graph LR
    A["Infant with RDS on CPAP (6-8 cmH2O)"] --> B{"FiO2 >= 0.30 within first 6h?"}
    B -->|Yes| C["Prepare for Early LISA / MIST"]
    B -->|No| D["Continue CPAP Surveillance & Reassess"]
    C --> E["Apply Swaddling + Oral Sucrose (24%)"]
    E --> F["Video Laryngoscopy + Depth-Flagged 16-18G Catheter"]
    F --> G["Fractional Surfactant Instillation (1-3 min)"]
    G --> H["Maintain CPAP + Rapidly Wean FiO2"]
    H --> I{"Stable at 72 Hours?"}
    I -->|Yes| J["LISA Success: Avoided Mechanical Ventilation & BPD"]
    I -->|No| K["LISA Failure: Timely Intubation & Lung-Protective MV"]

    style C fill:#dcfce7,stroke:#16a34a,stroke-width:2px;
    style G fill:#f0fdf4,stroke:#22c55e,stroke-width:2px;
    style J fill:#bbf7d0,stroke:#15803d,stroke-width:3px;
    style K fill:#fee2e2,stroke:#ef4444,stroke-width:2px;

Prioritize Non-Invasive Management: Primary Bubble CPAP ($6-8\text{ cmH}_2\text{O}$) combined with early LISA/MIST represents the contemporary standard of care for preterm infants with RDS.
Timing is Paramount: Administer surfactant early (within the first $2-6\text{ hours}$ of life) once $FiO_2$ thresholds ($\ge 0.30$) are met, preventing progressive alveolar collapse and secondary surfactant inactivation.
Preserve Spontaneous Breathing: Never administer paralytics; use non-pharmacological comfort measures or carefully titrated light analgosedation (ketamine/low-dose fentanyl) to ensure continuous negative pleural pressure swings.
Depth and Speed Control: Strictly calculate catheter depth [$\text{Weight (kg)} + 5.5-6.0\text{ cm}$ or $1.0-1.5\text{ cm}$ below cords] with visual flag marking to prevent endobronchial intubation. Deliver boluses slowly over $1-3\text{ minutes}$ to eliminate reflux.
Vigilant Post-Procedural Weaning: Anticipate rapid compliance improvement and immediately wean $FiO_2$ to prevent hyperoxia while maintaining CPAP stability to safeguard functional residual capacity.